Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Hilma J. van der Horst(Amsterdam University Medical Centers), Tuna Mutis(Amsterdam Neuroscience), Daphne de Jong(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Martine E.D. Chamuleau(Hovon), Margaretha G.M. Roemer, Esther C.W. Breij(Genmab (Netherlands)), Hendrik F. van Essen(Amsterdam University Medical Centers), Nathalie J. Hijmering(Amsterdam University Medical Centers), Daniella R. A. I. Berry(Amsterdam University Medical Centers), Sonja Zweegman(Vrije Universiteit Amsterdam), Ida H. Hiemstra(Genmab (Netherlands)), A. Vera de Jonge(Amsterdam Neuroscience), Anne T. Gelderloos(National Institute for Public Health and the Environment)
Cited by 95
Related Papers
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
|Blood|2019|136
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
|The Lancet Haematology|2024|134
A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex
|The Journal of Immunology|1991|128
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
|The Lancet Haematology|2018|116